Table of Contents

1 Industry Overview of Urological Cancer Therapeutics Drugs

• 1.1 Brief Introduction of Urological Cancer Therapeutics Drugs
• 1.2 Classification of Urological Cancer Therapeutics Drugs
• 1.3 Applications of Urological Cancer Therapeutics Drugs
• 1.4 Market Analysis by Countries of Urological Cancer Therapeutics Drugs
  • 1.4.1 United States Status and Prospect (2014-2024)
  • 1.4.2 Canada Status and Prospect (2014-2024)
  • 1.4.3 Germany Status and Prospect (2014-2024)
  • 1.4.4 France Status and Prospect (2014-2024)
  • 1.4.5 UK Status and Prospect (2014-2024)
  • 1.4.6 Italy Status and Prospect (2014-2024)
  • 1.4.7 Russia Status and Prospect (2014-2024)
  • 1.4.8 Spain Status and Prospect (2014-2024)
  • 1.4.9 China Status and Prospect (2014-2024)
  • 1.4.10 Japan Status and Prospect (2014-2024)
  • 1.4.11 Korea Status and Prospect (2014-2024)
  • 1.4.12 India Status and Prospect (2014-2024)
  • 1.4.13 Australia Status and Prospect (2014-2024)
  • 1.4.14 New Zealand Status and Prospect (2014-2024)
  • 1.4.15 Southeast Asia Status and Prospect (2014-2024)
  • 1.4.16 Middle East Status and Prospect (2014-2024)
  • 1.4.17 Africa Status and Prospect (2014-2024)
  • 1.4.18 Mexico East Status and Prospect (2014-2024)
  • 1.4.19 Brazil Status and Prospect (2014-2024)
  • 1.4.20 C. America Status and Prospect (2014-2024)
  • 1.4.21 Chile Status and Prospect (2014-2024)
  • 1.4.22 Peru Status and Prospect (2014-2024)
  • 1.4.23 Colombia Status and Prospect (2014-2024)

2 Major Manufacturers Analysis of Urological Cancer Therapeutics Drugs

• 2.1 Company 1
  • 2.1.1 Company Profile
  • 2.1.2 Product Picture and Specifications
  • 2.1.3 Capacity, Sales, Price, Cost, Gross and Revenue
  • 2.1.4 Contact Information
• 2.2 Company 2
  • 2.2.1 Company Profile
  • 2.2.2 Product Picture and Specifications
  • 2.2.3 Capacity, Sales, Price, Cost, Gross and Revenue
  • 2.2.4 Contact Information
• 2.3 Company 3
  • 2.3.1 Company Profile
  • 2.3.2 Product Picture and Specifications
  • 2.3.3 Capacity, Sales, Price, Cost, Gross and Revenue
  • 2.3.4 Contact Information
• 2.4 Company 4
  • 2.4.1 Company Profile
  • 2.4.2 Product Picture and Specifications
  • 2.4.3 Capacity, Sales, Price, Cost, Gross and Revenue
  • 2.4.4 Contact Information
• 2.5 Company 5
  • 2.5.1 Company Profile
  • 2.5.2 Product Picture and Specifications
  • 2.5.3 Capacity, Sales, Price, Cost, Gross and Revenue
  • 2.5.4 Contact Information
• 2.6 Company 6
  • 2.6.1 Company Profile
  • 2.6.2 Product Picture and Specifications
  • 2.6.3 Capacity, Sales, Price, Cost, Gross and Revenue
  • 2.6.4 Contact Information
• 2.7 Company 7
  • 2.7.1 Company Profile
  • 2.7.2 Product Picture and Specifications
  • 2.7.3 Capacity, Sales, Price, Cost, Gross and Revenue
  • 2.7.4 Contact Information
• 2.8 Company 8
  • 2.8.1 Company Profile
  • 2.8.2 Product Picture and Specifications
  • 2.8.3 Capacity, Sales, Price, Cost, Gross and Revenue
  • 2.8.4 Contact Information
• 2.9 Company 9
  • 2.9.1 Company Profile
  • 2.9.2 Product Picture and Specifications
  • 2.9.3 Capacity, Sales, Price, Cost, Gross and Revenue
  • 2.9.4 Contact Information
• 2.10 Company 10
  • 2.10.1 Company Profile
  • 2.10.2 Product Picture and Specifications
  • 2.10.3 Capacity, Sales, Price, Cost, Gross and Revenue
  • 2.10.4 Contact Information

. . .

3 Global Price, Sales and Revenue Analysis of Urological Cancer Therapeutics Drugs by Regions, Manufacturers, Types and Applications

• 3.1 Global Sales and Revenue of Urological Cancer Therapeutics Drugs by Regions 2014-2019
• 3.2 Global Sales and Revenue of Urological Cancer Therapeutics Drugs by Manufacturers 2014-2019
• 3.3 Global Sales and Revenue of Urological Cancer Therapeutics Drugs by Types 2014-2019
• 3.4 Global Sales and Revenue of Urological Cancer Therapeutics Drugs by Applications 2014-2019
• 3.5 Sales Price Analysis of Global Urological Cancer Therapeutics Drugs by Regions, Manufacturers, Types and Applications in 2014-2019

4 North America Sales and Revenue Analysis of Urological Cancer Therapeutics Drugs by Countries

• 4.1. North America Urological Cancer Therapeutics Drugs Sales and Revenue Analysis by Countries (2014-2019)
• 4.2 United States Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)
• 4.3 Canada Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)

5 Europe Sales and Revenue Analysis of Urological Cancer Therapeutics Drugs by Countries

• 5.1. Europe Urological Cancer Therapeutics Drugs Sales and Revenue Analysis by Countries (2014-2019)
• 5.2 Germany Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)
• 5.3 France Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)
• 5.4 UK Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)
• 5.5 Italy Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)
• 5.6 Russia Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)
• 5.7 Spain Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)

6 Asia Pacifi Sales and Revenue Analysis of Urological Cancer Therapeutics Drugs by Countries

• 6.1. Asia Pacifi Urological Cancer Therapeutics Drugs Sales and Revenue Analysis by Countries (2014-2019)
• 6.2 China Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)
• 6.3 Japan Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)
• 6.4 Korea Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)
• 6.5 India Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)
• 6.6 Australia Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)
• 6.7 New Zealand Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)
• 6.8 Southeast Asia Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)

7 Latin America Sales and Revenue Analysis of Urological Cancer Therapeutics Drugs by Countries

• 7.1. Latin America Urological Cancer Therapeutics Drugs Sales and Revenue Analysis by Countries (2014-2019)
• 7.2 Mexico Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)
• 7.3 Brazil Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)
• 7.4 C. America Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)
• 7.5 Chile Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)
• 7.6 Peru Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)
• 7.7 Colombia Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)

8 Middle East & Africa Sales and Revenue Analysis of Urological Cancer Therapeutics Drugs by Countries

• 8.1. Middle East & Africa Urological Cancer Therapeutics Drugs Sales and Revenue Analysis by Countries (2014-2019)
• 8.2 Middle East Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)
• 8.3 Africa Urological Cancer Therapeutics Drugs Sales, Revenue and Growth Rate (2014-2019)

9 Global Market Forecast of Urological Cancer Therapeutics Drugs by Regions, Countries, Manufacturers, Types and Applications

• 9.1 Global Sales and Revenue Forecast of Urological Cancer Therapeutics Drugs by Regions 2019-2024
• 9.2 Global Sales and Revenue Forecast of Urological Cancer Therapeutics Drugs by Manufacturers 2019-2024
• 9.3 Global Sales and Revenue Forecast of Urological Cancer Therapeutics Drugs by Types 2019-2024
• 9.4 Global Sales and Revenue Forecast of Urological Cancer Therapeutics Drugs by Applications 2019-2024
• 9.5 Global Revenue Forecast of Urological Cancer Therapeutics Drugs by Countries 2019-2024
  • 9.5.1 United States Revenue Forecast (2019-2024)
  • 9.5.2 Canada Revenue Forecast (2019-2024)
  • 9.5.3 Germany Revenue Forecast (2019-2024)
  • 9.5.4 France Revenue Forecast (2019-2024)
  • 9.5.5 UK Revenue Forecast (2019-2024)
  • 9.5.6 Italy Revenue Forecast (2019-2024)
  • 9.5.7 Russia Revenue Forecast (2019-2024)
  • 9.5.8 Spain Revenue Forecast (2019-2024)
  • 9.5.9 China Revenue Forecast (2019-2024)
  • 9.5.10 Japan Revenue Forecast (2019-2024)
  • 9.5.11 Korea Revenue Forecast (2019-2024)
  • 9.5.12 India Revenue Forecast (2019-2024)
  • 9.5.13 Australia Revenue Forecast (2019-2024)
  • 9.5.14 New Zealand Revenue Forecast (2019-2024)
  • 9.5.15 Southeast Asia Revenue Forecast (2019-2024)
  • 9.5.16 Middle East Revenue Forecast (2019-2024)
  • 9.5.17 Africa Revenue Forecast (2019-2024)
  • 9.5.18 Mexico East Revenue Forecast (2019-2024)
  • 9.5.19 Brazil Revenue Forecast (2019-2024)
  • 9.5.20 C. America Revenue Forecast (2019-2024)
  • 9.5.21 Chile Revenue Forecast (2019-2024)
  • 9.5.22 Peru Revenue Forecast (2019-2024)
  • 9.5.23 Colombia Revenue Forecast (2019-2024)

10 Industry Chain Analysis of Urological Cancer Therapeutics Drugs

• 10.1 Upstream Major Raw Materials and Equipment Suppliers Analysis of Urological Cancer Therapeutics Drugs
  • 10.1.1 Major Raw Materials Suppliers with Contact Information Analysis of Urological Cancer Therapeutics Drugs
  • 10.1.2 Major Equipment Suppliers with Contact Information Analysis of Urological Cancer Therapeutics Drugs
• 10.2 Downstream Major Consumers Analysis of Urological Cancer Therapeutics Drugs
• 10.3 Major Suppliers of Urological Cancer Therapeutics Drugs with Contact Information
• 10.4 Supply Chain Relationship Analysis of Urological Cancer Therapeutics Drugs

11 New Project Investment Feasibility Analysis of Urological Cancer Therapeutics Drugs

• 11.1 New Project SWOT Analysis of Urological Cancer Therapeutics Drugs
• 11.2 New Project Investment Feasibility Analysis of Urological Cancer Therapeutics Drugs
  • 11.2.1 Project Name
  • 11.2.2 Investment Budget
  • 11.2.3 Project Product Solutions
  • 11.2.4 Project Schedule

12 Conclusion of the Global Urological Cancer Therapeutics Drugs Industry Market Research 2019

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Author Details

The Urological Cancer Therapeutics Drugs market was valued at XX Million US$ in 2018 and is projected to reach XX Million US$ by 2024, at a CAGR of XX% during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2024 as the forecast period to estimate the market size for Urological Cancer Therapeutics Drugs.
Global Urological Cancer Therapeutics Drugs industry market professional research 2014-2024, is a report which provides the details about industry overview, industry chain, market size (sales, revenue, and growth rate), gross margin, major manufacturers, development trends and forecast.

Key players in global Urological Cancer Therapeutics Drugs market include:
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.

Market segmentation, by product types:
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)

Market segmentation, by applications:
Hospital
Medical Research Laboratory
Others

Market segmentation, by regions:
North America (United States, Canada)
Europe (Germany, France, UK, Italy, Russia, Spain)
Asia Pacific (China, Japan, Korea, India, Australia, New Zealand)
Middle East & Africa (Middle East, Africa)
Latin America (Mexico, Brazil, C. America, Chile, Peru, Colombia)

The report can answer the following questions:
1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Urological Cancer Therapeutics Drugs industry.
2. Global major manufacturers’ operating situation (sales, revenue, growth rate and gross margin) of Urological Cancer Therapeutics Drugs industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Urological Cancer Therapeutics Drugs industry.
4. Different types and applications of Urological Cancer Therapeutics Drugs industry, market share of each type and application by revenue.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to2024 of Urological Cancer Therapeutics Drugs industry.
6. Upstream raw materials and manufacturing equipment, industry chain analysis of Urological Cancer Therapeutics Drugs industry.
7. SWOT analysis of Urological Cancer Therapeutics Drugs industry.
8. New Project Investment Feasibility Analysis of Urological Cancer Therapeutics Drugs industry.